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ABSTRACT
The introduction of first-generation drug-
eluting stents (DES) was a major advance in
the percutaneous treatment of coronary artery
disease, with DES significantly reducing the
incidence of restenosis and major adverse
coronary events compared with bare metal
stents. Next-generation DES now utilizes lower
profiles, thinner struts, and other technological
advances to help extend their safety and
efficacy. Importantly, studies of next-
generation devices have now gone beyond
controlled clinical trials with selected
populations to registries and studies with all-
comer populations, where more diverse and
complex sets of patients and lesions have been
managed. Thus, a large body of evidence and
comparative data about the safety and efficacy
of these devices has accumulated. The
ResoluteTM zotarolimus-eluting stent (R-ZES;
Medtronic Inc., Santa Rosa, CA, USA) is a
next-generation DES that uses a novel
biocompatible polymer on a cobalt alloy stent
platform to extend the duration of drug elution
and improve the stent’s efficacy. The
IntegrityTM platform (Medtronic, Inc., Santa
Rosa, CA, USA) used in the most recent
iteration of the R-ZES stent further enhances
the flexibility and deliverability of the stent in
complex lesions by incorporation of a
continuous sinusoidal design. In the following
review, the clinical data is critically examined
for the R-ZES and discuss its performance using
comparative data currently available for next-
generation DES. It is concluded that R-ZES use
in complex patients and lesions is associated
with durable efficacy and safety and represents
another generational improvement in DES
technology, which undoubtedly will enhance
patient outcomes postpercutaneous coronary
interventional.
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Drug-eluting stents (DES) have not only
improved clinical outcomes compared with
bare metal stents (BMS), they have vastly
enhanced our capability and confidence to
tackle increasingly complex patients and
lesions traditionally treated with coronary
artery bypass graft surgery (CABG) [1–3]. This
has in turn increased percutaneous coronary
interventional (PCI) procedural volumes
worldwide and DES use in clinical and
angiographic scenarios not initially tested
and approved by the U.S. Food and Drug
Administration (FDA), otherwise referred to as
off-label use. The result has been justifiable
concerns regarding the efficacy and associated
risk of DES in these situations. However, these
concerns have been continually addressed by
carefully collected outcomes analyses from
large longitudinal registries, data from
randomized controlled trials (RCTs), and
translational research studies combined with
advances in DES technology. Importantly, this
effort has been a result of unprecedented
collaboration between regulatory bodies,
industry, and the interventional community.
In this review, the clinical outcome data of
the most recently FDA-approved DES are
critically examined, the ResoluteTM
zotarolimus-eluting stent (R-ZES, Medtronic,
Inc., Santa Rosa, CA, USA), and the unique
features of the next iteration of the R-ZES
built on the IntegrityTM platform (Medtronic,
Inc., Santa Rosa, CA, USA) to further enhance
stent flexibility and deliverability, especially in
complex lesions.
R-ZES
The Integrity BMS is a new iteration of the
DriverTM BMS (Medtronic, Inc., Santa Rosa, CA,
USA); the zotarolimus-eluting version is the
Resolute Integrity stent where Integrity BMS
replaces the Driver platform in the new stent.
The Integrity stent platform uses a single cobalt
chromium wire to form a continuous sinusoidal
pattern of crowns and struts wrapped helically
around a mandrel with a 0.09 mm strut
thickness and a 1.12 mm crossing profile. This
unique manufacturing technology enhances
stent flexibility, deliverability, and
conformability without sacrificing radial
strength [4]. A study of stent longitudinal
distortion tested seven stent platforms
including the EndeavorTM Driver (Medtronic,
Inc., Santa Rosa, CA, USA), Resolute Integrity
(Medtronic, Inc., Santa Rosa, CA, USA),
LiberteTM (Boston Scientific, Natick, MA, USA),
OmegaTM Promus ElementTM (Boston Scientific,
Natick, MA, USA), Multilink 8Xience PrimeTM
(Abbott Vascular, Santa Clara, CA, USA), and
VisionTM Xience VTM (Abbott Vascular, Santa
Clara, CA, USA) [5]. The Resolute Integrity DES
was more resistant to longitudinal distortion in
elongation tests than the Omega Element or
Driver stents, and similar to the other stents
tested. The authors note that ideally there must
be a balance between stent flexibility and
stiffness which has been shown to correlate
with the number of connectors between hoops
[6]. The Resolute Integrity and the Driver
platform have two connections compared with
three for Xience V and Xience Prime stents, but
the unique helical single-wire design decreases
the longitudinal distortion of the Resolute
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Integrity stent thus maintaining a balance
between flexibility and longitudinal integrity
[5, 6].
Radial strength is primarily responsible for
creating and maintaining vessel patency and
studies have shown it to be an important
predictor of clinical performance [7–9]. In-
house testing at Medtronic has shown
equivalence in radial strength between the
Driver and Integrity stents. Performance of the
Resolute Integrity stent platform was compared
with five other contemporary stents deployed in
an idealized vessel using finite element
simulations [7]. Percent malposition of stent
struts, defined as the strut distance from the wall
[10 lm was least with the Resolute Integrity
platform at 9% and maximal with the Promus
Element stent at 43% [10]. Furthermore, these
investigators used finite element analysis
correlated with bench testing of radial
strength and demonstrated similar radial
strength to the Promus Element stent
(*0.012 mm/N diameter reduction at given
force) and greater radial strength than the
Multilink Vision (*0.16 mm/N) or Xience
Prime stents (*0.018 mm/N diameter
reduction) (Personal Communication).
The R-ZES is covered with a proprietary
BioLinxTM (Medtronic, Inc., Santa Rosa, CA,
USA) tripolymer, a blend of the hydrophilic C19
polymer, polyvinyl pyrrolidinone (PVP) and the
hydrophobic C10 polymer. The PVP
component results in an overall hydrophilic
polymer which enhances the biocompatibility
of the stent [11]. There is an initial release of
zotarolimus from the surface of the stent
followed by extended drug elution. Nearly
85% of the zotarolimus (dose density *1.6 lg/
mm2) is released by 60 days, and completely by
180 days [11].
The thin strut, low profile, and continuous
sinusoidal design combined with the
biocompatible polymer and extended drug
release is designed to maximize deliverability
and efficacy of this new generation R-ZES.
However, the evidence regarding its long-term
safety for complex patient subsets also needs to
be critically examined. This review will
summarize the clinical data for the R-ZES and
discuss results in the context of complex ‘‘real-
world’’ PCI.
METHODS
The PubMed database was used to identify all
prospective clinical trials for the R-ZES and the
everolimus-eluting stent (EES) for the past
5 years. Related presentations for the past
2 years were obtained from the Transcatheter
Cardiovascular Therapeutics, American College
of Cardiology, and PCRonline websites. The
PubMed database was also searched for
preclinical data using a zotarolimus-eluting
stent, Biolinx polymer, coronary stent design,
and coronary stent performance search terms.
Additional data related to stent design and
performance was requested from Medtronic,
Inc.
R-ZES CLINICAL STUDIES
The first-in-man R-ZES experience (RESOLUTE
study) was a 139 patient, multicenter,
prospective study examining 9-month in-stent
late loss and target lesion revascularization
(TLR) in stenotic de novo lesions in coronary
vessels with reference vessel diameter between
2.5 and 3.5 mm in diameter and 14 mm to
27 mm in length [12]. The study required a
4-month angiographic and intra-vascular
ultrasound (IVUS) follow-up in the first 30
patients and a 9-month follow-up in the
remainder. Complex patients with recent
Cardiol Ther (2013) 2:17–25 19
123
myocardial infarction, left ventricular ejection
fraction (LVEF) \30% and ostial, bifurcation,
heavily calcified, or left main lesions were
excluded. Dual anti-platelet therapy (DAPT)
with aspirin and clopidogrel was prescribed for
6 months post-PCI, and aspirin continued
indefinitely thereafter. The 9-month in-stent
late lumen loss was 0.22 ± 0.27 mm. TLR rates
at 9 months, 1, 2, and 4 years were 0.0%, 0.8%,
1.5%, and 2.3%, respectively. The Academic
Research Consortium (ARC)-defined definite
and probable stent thrombosis (ST) events at
4 years remained at 0.0% [12, 13]. Though this
experience was restrictive and may not reflect
‘‘real-world’’ DES use, it certainly set the best-
case reference of R-ZES performance.
The results from the single-arm RESOLUTE
US trial (R-US), which included 1,402 patients
with 1- or 2-vessel coronary artery disease from
116 US centers with lesions suitable for
2.25–4.0 mm R-ZES was reported in April 2011
[14]. Though the main analysis was performed
on a prespecified group of single-lesion patients
treated with 2.5–3.5 mm R-ZES, a 241 patient
cohort received the 2.25 mm R-ZES or had two
lesions treated. The study enrolled 1,242
patients in the clinical cohort. The overall
(2.25–4.0 mm) target lesion failure (TLF) rate
was 4.7%, and rates of cardiac death,
myocardial infarction (MI), and TLR were
0.7%, 1.4%, and 2.8%, respectively. The
12-month rate of ST was 0.1% [15].
The RESOLUTE all-comers (R-AC) trial was
an international, multicenter RCT including
2,292 patients with an open-label random
assignment of a wide variety of unrestricted
coronary lesions in a 1:1 fashion to either R-ZES
or EES [16]. There were no restrictions on the
number of lesions, vessels, or number of
implanted stents. Most importantly, 1,520
patients were defined as complex based on
prespecified definition, with a well-balanced
allocation to R-ZES (764 patients and 1,227
lesions) and EES (756 patients and 1,242
lesions) groups. The definition of complex
patients is shown in Table 1.
The primary 12-month noninferiority
endpoint of TLF, defined as a composite of
cardiac death, target vessel MI, and clinically
indicated TLR, was met (R-ZES 8.2% vs. EES
8.3%, noninferiority P\0.001) [16]. The mean
SYNTAXTM (Boston Scientific, Natick, MA, USA)
score was 16.6 ± 9.4 in the complex R-ZES
patients, compared with 11.2 ± 7.9 in the
simple R-ZES patients [17]. Patients with
recent acute MI, diabetes mellitus (DM), and
LVEF \35% constituted 43.5%, 23.1%, and
3.8% of the complex patient cohort,
respectively. Bifurcation, left main, saphenous
vein graft, and chronic total occlusion PCI were
performed in 26%, 3.1%, 3.5%, and 25% of
Table 1 Prespeciﬁed deﬁnition of complex patients in
RESOLUTE all-comers trial [16]
Complex patients criteria
(presence of at least one of the following)
Acute myocardial infarction within 72 h
Left ventricular ejection fraction\30%
Renal insufﬁciency or failure (serum creatinine
C140 lmol/L)
Treatment of bifurcation coronary lesions
Treatment of saphenous vein graft lesions
Treatment of arterial graft lesions
Treatment of in-stent restenosis lesions
Treatment of unprotected left main coronary lesions
Treatment of C2 coronary vessels
Treatment of coronary lesions C27 mm in length
Treatment of[1 lesion per coronary vessel
Treatment of coronary vessels with presence of
thrombus
Treatment of coronary total occlusions
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complex patients. Overall, TLF was 6.3% and
9.3% (P = 0.015) at 1 year for simple and
complex patients, respectively. Similarly, target
vessel failure (TVF) in the entire study, defined
as a composite of cardiac death, target-vessel
MI, and clinically indicated target vessel
revascularization (TVR) was 7.1% and 10.4%
(P = 0.009) at 1 year for simple and complex
patients, respectively. A patient oriented 1-year
composite endpoint including all cause death,
MI, and any repeat revascularization was
identified as a secondary clinical endpoint and
was also higher for complex patients compared
with simple (16.1% vs. 11.6%, P = 0.004).
Definite or probable ST occurred in 2.2% of
complex patients and in 1.35% of simple
patients, with no difference between the R-ZES
and EES groups (P value for interaction = 0.14)
[17].
Prespecified 2-year clinical outcomes of the
R-AC trial demonstrated sustained safety and
efficacy for the R-ZES and EES [18]. The rates of
TLF at 3 years were 13.1% for R-ZES and 12.4%
for EES (P = 0.614). Additionally, the rates of
definite or probable ST at 3 years were also low
[19]. Rates of definite or probable very late stent
thrombosis (VLST) were 0.5% for both stents.
DAPT use was 84.4 and 83.5% at 1 year for the
R-ZES and EES groups, respectively (P = 0.60).
The RESOLUTE International Trial (R-Int)
trial enrolled an unrestricted cohort of 2,349
patients, two-thirds of which were complex
with at least one R-ZES (2.25–4.0 mm stent
diameter). Nearly 30% of patients were
diabetic and 46% presented with an acute
coronary syndrome (ACS). The composite
primary endpoint of cardiac death and target
vessel MI at 1 year was 4.3% [20].
The pooled RESOLUTE clinical program
derived from five R-ZES studies (RESOLUTE,
R-US, R-AC, R-Int and RESOLUTE Japan)
includes 5,130 patients [21]. Nearly 30% of
patients had DM and 46% were complex. The
diabetic cohort was older with expectedly more
patients with hypertension, hyperlipidemia, or
prior PCI. At 2 years, clinically-driven TLR was
4.7% and definite or probable ST was 0.9%. In a
prespecified analysis of less complex patients
with DM, 2-year rates of clinically-driven TLR
and definite or probable ST for patients with
DM (n = 861) was 4.8% and 0.3%, respectively
(Fig. 1) [21]. In the nondiabetic cohort
(n = 1,903) these 2-year endpoints were
reached in 3.4% and 0.4% patients,
respectively. These data indicate consistently
low event rates and durable clinical outcomes in
the higher-risk patients with DM. Based on
these data the R-ZES is the first DES approved by
the FDA for use in patients with DM.
The diabetic population included 29.6% of
patients with insulin-dependent DM. At 1 year,
event rates were significantly higher in patients
with insulin-dependent diabetes mellitus IDDM
compared with those without DM (TLR 6.3% vs.
2.9% [P\0.001]; cardiac death or MI 6.6% vs.
3.6% [P = 0.003]; ST 1.5% vs. 0.7% [P = 0.02])
[22]. The cumulative incidence of TLF, cardiac
Fig. 1 Two-year event rates for standard-risk patients with
diabetes mellitus (n = 861) in the pooled RESOLUTE
global clinical program [21] ST stent thrombosis, TLF
target lesion failure, TLR target lesion revascularization,
TVF target vessel failure, TVMI target vessel myocardial
infarction
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death, target vessel MI, and TLR was similar for
DM patients receiving the R-ZES (7.8%) and the
EES (9.0%) at 1 year (P = 0.96); there was a trend
to lower TLF in the non-DM patients (R-ZES
6.1%; EES 8.3%; [P = 0.09]). One year outcomes
for R-ZES and EES DM patients were also similar
for rates of TLR, cardiac death or MI, and ST
[22]. These data also indicate to the strength
of the RESOLUTE pooled clinical program
which was conceptualized using similar
event definitions, adjudication, and data
management methodology across a myriad of
R-ZES trials. It is imperative that data from this
large and diverse cohort of patients representing
a ‘‘real-world’’ patient population will continue
to be the source of important data and guide
contemporary PCI practice worldwide.
R-ZES RESULTS IN PERSPECTIVE
Stefanini et al. [17] compared the R-ZES results
from the R-AC RCT to other RCTs with ‘‘all
comer’’ patients. In the Sirolimus-Eluting and
Paclitaxel-Eluting Stents for Coronary
Revascularization (SIRTAX) trial, 12-month
clinically-driven TLR and definite ST rate were
8.9% and 1.9%, respectively [23]. In the Limus
Eluted From A Durable Versus ERodable Stent
Coating (LEADERS) trial, though only a fifth of
the patients had angiographic follow-up,
clinically-driven TLR and definite ST rates
were 5.5% and 2.0% at 12 months,
respectively [24]. The Randomized Controlled
Trial of Everolimus-eluting Stents and
Paclitaxel-eluting Stents for Coronary
Revascularization in Daily Practice (COMPARE)
trial reported a 1-year clinically driven TLR of
2% and a definite ST rate of 0.4% [25]. There
was no angiographic follow-up in the
COMPARE trial. The results from the R-ZES
trials, especially R-AC, compared very favorably
with other all-comer studies, while including a
much more complex patient population and
lesion categories. A meta-analysis of 76 RCTs
with 117,762 patient-years of follow-up found
considerable variations in the magnitude of
long-term TVR rates (39–61%) by DES type (ZES-
R = EES[paclitaxel-eluting stent[ZES[BMS).
Overall, there was no long-term increase in
death with any of the DES [26]. In the R-AC
trial, R-ZES was associated with a higher definite
stent thrombosis at 1 year than EES (1.2% vs.
0.3%; [P = 0.01]), while definite or probable
stent thrombosis at 2 years were 1.9% and 1.0%
(P = 0.08) for R-ZES and EES, respectively [16,
18] However, in the TWENTE trial, definite or
probable ST rates for R-ZES and EES were 0.9%
and 1.2%, respectively (P = 0.59). Definite ST
rates were also low (0.58% and 0%, respectively
[P = 0.12]) [27]. Comparative data of ST across
R-ZES and EES studies is shown in Fig. 2 [16, 20,
25, 27–34]. It is important to note that these
data are not based on direct comparisons and
on studies not powered for the low frequency ST
event. These data suggest a very low risk of ST
with R-ZES and EES stents and the observed
differences are caused by chance.
Patti et al. [35] reported in a 2008 meta-
analysis of nine studies comparing DES with
BMS in DM patients, including 1,141 patients,
an in-stent restenosis (ISR) and TLR rates with
BMS of 41% and 27%, significantly higher than
first generation DES ISR and TLR rates of 8%
and 8%, respectively (P\0.0001 for both
comparisons). In a pooled analysis of EES
versus paclitaxel-eluting stent from the SPIRIT
and COMPARE trials, ischemia-driven TLR rates
were 6.1% and 5.5% for diabetics in the
paclitaxel-eluting and EES recipients,
respectively (P = 0.60); it was 6.9% and 3.6%,
respectively in nondiabetics (P\0.0001) [36]. In
a more recent all-comer DES study presented by
Jensen et al., TVR rates in patients with DM with
sirolimus-eluting stent and EES were 10.7% and
22 Cardiol Ther (2013) 2:17–25
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6.7% at 18 months, respectively [37]. While this
subgroup analysis was not powered to assess
these endpoints, these data support the
observation that significant strides have been
made with respect to PCI outcomes in diabetics
with complex coronary artery disease
revascularized percutaneously with R-ZES.
CONCLUSION
R-ZES use in complex patients and lesions is
associated with durable efficacy and safety and
represents another generational improvement
in DES technology, which will undoubtedly
enhance patient outcomes post-PCI.
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Fig. 2 Stent thrombosis across RESOLUTE and everoli-
mus-eluting stent trials. ARC deﬁnite and probable ST at
12 months from 10 ‘‘real-world’’ clinical trials. It is
important to note that these data are not based on direct
comparisons and on studies not powered for the low
frequency ST event. ARC Academic Research Consortium,
COMPARE Second-Generation Everolimus-Eluting and
Paclitaxel-Eluting Stents in Real-Life Practice, ESTROFA-2
Estudio Espanol Sobre Trombosis de Stents Farmacoactivos
de Segunda Generacion-2, ISAR Individualizable Drug-
Eluting Stent System to Abrogate Restenosis, LESSON 1
Long-term Comparison of Everolimus-Eluting and Siroli-
mus-Eluting Stents for Coronary Revascularization, R-Int
RESOLUTE International, RISICO Resolute Italian Study
in All Comers, ST stent thrombosis
Cardiol Ther (2013) 2:17–25 23
123
REFERENCES
1. Katritsis DG, Karvouni E, Ioannidis JP. Meta-
analysis comparing drug-eluting stents with bare
metal stents. Am J Cardiol. 2005;95:640–3.
2. Stettler C, Wandel S, Allemann S, et al. Outcomes
associated with drug-eluting and bare-metal stents:
a collaborative network meta-analysis. Lancet.
2007;370:937–48.
3. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14
trials comparing sirolimus-eluting stents with bare-
metal stents. N Eng J Med. 2007;356:1030–9.
4. Lee SW, Chan MP, Chan KK. Acute and 16-month
outcomes of a new stent: the first-in-man
evaluation of the Medtronic S9 (integrity) stent.
Catheter Cardiovasc Interv. 2011;78:898–908.
5. Ormiston JA, Webber B, Webster MW. Stent
longitudinal integrity bench insights into a
clinical problem. JACC Cardiovasc Interv.
2011;4:1310–7.
6. Ormiston JA, Dixon SR, Webster MW, et al. Stent
longitudinal flexibility: a comparison of 13 stent
designs before and after balloon expansion.
Catheter Cardiovasc Interv. 2000;50:120–4.
7. Escaned J, Goicolea J, Alfonso F, et al. Propensity
and mechanisms of restenosis in different coronary
stent designs: complementary value of the analysis
of the luminal gain-loss relationship. J Am Coll
Cardiol. 1999;34:1490–7.
8. Kastrati A, Dirschinger J, Boekstegers P, et al.
Influence of stent design on 1-year outcome after
coronary stent placement: a randomized
comparison of five stent types in 1,147 unselected
patients. Catheter Cardiovasc Interv. 2000;50:
290–7.
9. Kastrati A, Mehilli J, Dirschinger J, et al. Restenosis
after coronary placement of various stent types. Am
J Cardiol. 2001;87:34–9.
10. Mortier P, De Beule M, Segers P, Verdonck P,
Verhegghe B. Virtual bench testing of new
generation coronary stents. EuroIntervention.
2011;7:369–76.
11. Udipi K, Melder RJ, Chen M, et al. The next
generation Endeavor Resolute Stent: role of the
BioLinx Polymer System. EuroIntervention.
2007;3:137–9.
12. Meredith IT, Worthley S, Whitbourn R, et al.
Clinical and angiographic results with the next-
generation resolute stent system: a prospective,
multicenter, first-in-human trial. JACC Cardiovasc
Interv. 2009;2:977–85.
13. Meredith IT, Worthley S, Whitbourn R, et al. The
next-generation Endeavor Resolute stent: 4-month
clinical and angiographic results from the Endeavor
Resolute first-in-man trial. EuroIntervention.
2007;3:50–3.
14. Mauri L, Leon MB, Yeung AC, Negoita M, Keyes MJ,
Massaro JM. Rationale and design of the clinical
evaluation of the Resolute Zotarolimus-Eluting
Coronary Stent System in the treatment of de
novo lesions in native coronary arteries (the
RESOLUTE US clinical trial). Am Heart J.
2011;161:807–14.
15. Yeung AC, Leon MB, Jain A, et al. Clinical
evaluation of the Resolute zotarolimus-eluting
coronary stent system in the treatment of de novo
lesions in native coronary arteries: the RESOLUTE
US clinical trial. J Am Coll Cardiol.
2011;57:1778–83.
16. Serruys PW, Silber S, Garg S, et al. Comparison of
zotarolimus-eluting and everolimus-eluting
coronary stents. N Engl J Med. 2010;363:136–46.
17. Stefanini GG, Serruys PW, Silber S, et al. The impact
of patient and lesion complexity on clinical and
angiographic outcomes after revascularization with
zotarolimus- and everolimus-eluting stents: a
substudy of the RESOLUTE All Comers Trial (a
randomized comparison of a zotarolimus-eluting
stent with an everolimus-eluting stent for
percutaneous coronary intervention). J Am Coll
Cardiol. 2011;57:2221–32.
18. Silber S, Windecker S, Vranckx P, Serruys PW.
Unrestricted randomised use of two new
generation drug-eluting coronary stents: 2-year
patient-related versus stent-related outcomes from
the RESOLUTE All Comers trial. Lancet.
2011;377:1241–7.
19. Silber S, Windecker S, Serruys PW, on behalf of the
RESOLUTE All Comers Investigators. Three-year
outcomes from the randomized comparison of a
Zotarolimus-eluting stent and an everolimus-
eluting stent in the RESOLUTE All Comers Trial.
EuroIntervention. 2012;8(Suppl. N):N16.
20. Neumann FJ, Widimsky P, Belardi JA. One-year
outcomes of patients with the zotarolimus-eluting
coronary stent: RESOLUTE International Registry.
EuroIntervention. 2012;7:1181–8.
21. Yeung AC, Leon M, Silber S, et al. The Resolute
zotarolimus-eluting stent in patients with diabetes
mellitus: two year outcomes. J Am Coll Cardiol.
2012;59(13 Suppl.):E97.
24 Cardiol Ther (2013) 2:17–25
123
22. Mauri L, Leon M, Yeung A, et al. The Resolute
zotarolimus-eluting stent in patients with diabetes
mellitus: one year outcomes. Eurointervention.
2011;7(Suppl. M).
23. Stefanini GG, Kalesan B, Pilgrim T, et al. Impact of
sex on clinical and angiographic outcomes among
patients undergoing revascularization with drug-
eluting stents. JACC Cardiovasc Interv.
2012;5:301–10.
24. Garg S, Sarno G, Serruys PW, et al. The twelve-
month outcomes of a biolimus eluting stent with a
biodegradable polymer compared with a sirolimus
eluting stent with a durable polymer.
EuroIntervention. 2010;6:233–9.
25. Kedhi E, Joesoef KS, McFadden E, et al. Second-
generation everolimus-eluting and paclitaxel-
eluting stents in real-life practice (COMPARE): a
randomised trial. Lancet. 2010;375:201–9.
26. Bangalore S, Kumar S, Fusaro M, et al. Short- and
long-term outcomes with drug-eluting and bare-
metal coronary stents: a mixed-treatment
comparison analysis of 117,762 patient-years of
follow-up from randomized trials. Circulation.
2012;125:2873–91.
27. von Birgelen C, Basalus MWZ, Tandjung K, et al. A
randomized controlled trial in second-generation
zotarolimus-eluting resolute stents versus
everolimus-eluting Xience V stents in real-world
patients: the TWENTE trial. J Am Coll Cardiol.
2012;59:1350–61.
28. Byrne RA, Kastrati A, Kufner S, et al. Randomized,
non-inferiority trial of three limus agent-eluting
stents with different polymer coatings: the
Intracoronary Stenting and Angiographic Results:
test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4)
Trial. Eur Heart J. 2009;30:2441–9.
29. Massberg S, Byrne RA, Kastrati A, et al. Polymer-free
sirolimus- and probucol-eluting versus new
generation zotarolimus-eluting stents in coronary
artery disease: the Intracoronary Stenting and
Angiographic Results: test Efficacy of Sirolimus-
and Probucol-Eluting versus Zotarolimus-eluting
Stents (ISAR-TEST 5) trial. Circulation.
2011;124:624–32.
30. Romagnoli E, Godino C, Ielasi A, et al. Resolute
Italian study in all comers: immediate and one-year
outcomes. Catheter Cardiovasc Interv.
2012;79:567–74.
31. Krucoff MW, Rutledge DR, Gruberg L, et al. A new
era of prospective real-world safety evaluation
primary report of XIENCE V USA (XIENCE V
Everolimus Eluting Coronary Stent System
condition-of-approval post-market study). JACC
Cardiovasc Interv. 2011;4:1298–309.
32. Ra¨ber L, Wohlwend L, Wigger M, et al. Five-year
clinical and angiographic outcomes of a
randomized comparison of sirolimus-eluting and
paclitaxel-eluting stents/clinical perspective.
Circulation. 2011;123:2819–28.
33. Raber L, Juni P, Nuesch E, et al. Long-term
comparison of everolimus-eluting and sirolimus-
eluting stents for coronary revascularization. J Am
Coll Cardiol. 2011;57:2143–51.
34. de la Torre Hernandez JM, Alfonso F, Gimeno F,
et al. Thrombosis of second-generation drug-eluting
stents in real practice results from the multicenter
Spanish registry ESTROFA-2 (Estudio Espanol Sobre
Trombosis de Stents Farmacoactivos de Segunda
Generacion-2). JACC Cardiovasc Interv.
2010;3:911–9.
35. Patti G, Nusca A, Di Sciascio G. Meta-analysis
comparison (nine trials) of outcomes with drug-
eluting stents versus bare metal stents in patients
with diabetes mellitus. Am J Cardiol.
2008;102:1328–34.
36. Stone GW, Kedhi E, Kereiakes DJ, et al. Differential
clinical responses to everolimus-eluting and
paclitaxel-eluting coronary stents in patients with
and without diabetes mellitus. Circulation.
2011;124:893–900.
37. Jensen LO, Thayssen P, Junker A, et al. Comparison
of outcomes in patients with versus without
diabetes mellitus after revascularization with
everolimus- and sirolimus-eluting stents (from the
SORT OUT IV Trial). Am J Cardiol. 2012;110:
1585–91.
Cardiol Ther (2013) 2:17–25 25
123
